IL118836A - Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan - Google Patents

Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Info

Publication number
IL118836A
IL118836A IL11883696A IL11883696A IL118836A IL 118836 A IL118836 A IL 118836A IL 11883696 A IL11883696 A IL 11883696A IL 11883696 A IL11883696 A IL 11883696A IL 118836 A IL118836 A IL 118836A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
aminoindan
disease
propargyl
injury
Prior art date
Application number
IL11883696A
Other languages
English (en)
Other versions
IL118836A0 (en
Original Assignee
Teva Pharma
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Technion Res & Dev Foundation filed Critical Teva Pharma
Priority to IL11883696A priority Critical patent/IL118836A/xx
Publication of IL118836A0 publication Critical patent/IL118836A0/xx
Priority to HU9904525A priority patent/HU226961B1/hu
Priority to AT97927353T priority patent/ATE328590T1/de
Priority to AU31880/97A priority patent/AU3188097A/en
Priority to EP97927353A priority patent/EP0929298B1/en
Priority to PCT/IL1997/000205 priority patent/WO1998002152A1/en
Priority to JP50580698A priority patent/JP4368421B2/ja
Priority to DE69736066T priority patent/DE69736066T2/de
Priority to CNB971971994A priority patent/CN1149985C/zh
Priority to CA002260037A priority patent/CA2260037C/en
Priority to NO19990088A priority patent/NO326052B1/no
Priority to US09/228,153 priority patent/US6277886B1/en
Publication of IL118836A publication Critical patent/IL118836A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11883696A 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan IL118836A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA002260037A CA2260037C (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP97927353A EP0929298B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
AT97927353T ATE328590T1 (de) 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan
AU31880/97A AU3188097A (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
HU9904525A HU226961B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
JP50580698A JP4368421B2 (ja) 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物
DE69736066T DE69736066T2 (de) 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(-)-n-propargyl-1-aminoindan
CNB971971994A CN1149985C (zh) 1996-07-11 1997-06-20 含s-(-)-n-炔丙基-1-氨基茚满的药物组合物
NO19990088A NO326052B1 (no) 1996-07-11 1999-01-08 Anvendelse av S-(-)-N-propargyl-1-aminoindamin eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament (a) for behandling av neurotrauma eller (b) for forbedring av hukommelsen hos en post-CHI-pasient.
US09/228,153 US6277886B1 (en) 1996-07-11 1999-01-11 Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Publications (2)

Publication Number Publication Date
IL118836A0 IL118836A0 (en) 1996-10-31
IL118836A true IL118836A (en) 2001-01-11

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Country Status (12)

Country Link
US (1) US6277886B1 (en:Method)
EP (1) EP0929298B1 (en:Method)
JP (1) JP4368421B2 (en:Method)
CN (1) CN1149985C (en:Method)
AT (1) ATE328590T1 (en:Method)
AU (1) AU3188097A (en:Method)
CA (1) CA2260037C (en:Method)
DE (1) DE69736066T2 (en:Method)
HU (1) HU226961B1 (en:Method)
IL (1) IL118836A (en:Method)
NO (1) NO326052B1 (en:Method)
WO (1) WO1998002152A1 (en:Method)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
ES2588780T3 (es) 2002-11-15 2016-11-04 Teva Pharmaceutical Industries Limited Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica
JP2007512319A (ja) * 2003-11-25 2007-05-17 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 心臓血管障害及び疾患を治療するための組成物及び方法
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP5738509B2 (ja) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド 内容物均一性が改善されたラサギリン製剤
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CN101325871B (zh) * 2005-12-09 2013-04-10 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil用于神经保护的用途
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
BRPI0718339A2 (pt) * 2006-12-14 2014-02-18 Teva Pharma Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
DK2101569T3 (da) * 2006-12-14 2012-01-30 Teva Pharma Krystallinsk fast rasagilinbase
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
US20100008983A1 (en) * 2008-06-10 2010-01-14 Muhammad Safadi Rasagiline soft gelatin capsules
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
CA2727017A1 (en) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Process for preparing and drying solid rasagiline base
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
PL2451771T3 (pl) 2009-07-09 2014-12-31 Ratiopharm Gmbh Sole rasagiliny i ich preparaty farmaceutyczne
EP3517103A1 (en) 2010-02-03 2019-07-31 Pharma Two B Ltd. Extended release formulations of rasagiline and uses thereof
RU2013108256A (ru) 2010-07-27 2014-09-10 Тева Фармасьютикал Индастриз Лтд. Дисперсии цитрата разагилина
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
EA201490760A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. R(+)-n-метилпропаргиламиноиндан
KR20140090996A (ko) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
MX2015002062A (es) 2012-08-17 2015-06-05 Teva Pharma Formulaciones parenterales de rasagilina.
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
WO1995018617A1 (en) * 1994-01-10 1995-07-13 Teva Pharmaceutical Industries Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
ATE328590T1 (de) 2006-06-15
AU3188097A (en) 1998-02-09
JP2000514453A (ja) 2000-10-31
CN1149985C (zh) 2004-05-19
HU226961B1 (en) 2010-03-29
HUP9904525A3 (en) 2000-12-28
US6277886B1 (en) 2001-08-21
DE69736066D1 (de) 2006-07-20
EP0929298B1 (en) 2006-06-07
NO326052B1 (no) 2008-09-08
WO1998002152A1 (en) 1998-01-22
HUP9904525A2 (hu) 2000-11-28
CA2260037A1 (en) 1998-01-22
NO990088D0 (no) 1999-01-08
CA2260037C (en) 2007-01-23
CN1227486A (zh) 1999-09-01
IL118836A0 (en) 1996-10-31
NO990088L (no) 1999-03-10
DE69736066T2 (de) 2006-12-28
EP0929298A1 (en) 1999-07-21
JP4368421B2 (ja) 2009-11-18

Similar Documents

Publication Publication Date Title
IL118836A (en) Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
HU913447D0 (en) Medical preparations and their use in treating neurologic disorders
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
MX9708977A (es) Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
CA2114251A1 (en) Igf-1 to improve the neural condition
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
AU1253495A (en) R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof
CA2122058A1 (en) Tgf-beta to improve neural outcome
WO1999045011A8 (en) Glycine transport inhibitors
HU9303748D0 (en) Composition of l-dopa-esters
CA2148194A1 (en) Cyclopeptides of the formula i
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
CA2139385A1 (en) Products containing g-csf and tnf binding protein
CA2374997A1 (en) Il6ril6 chimera for the treatment of neurodegenerative diseases
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
NZ268039A (en) Use of efaroxan in treating parkinson's disease
CA2097878A1 (en) Therapeutic agent for neutropenia
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired